US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

YARROW BIOSCIENCE, INC.

36.43

-1.7750-4.65%

Post-market: 36.430.00000.00%19:30 EDT

Volume:25.98K

Turnover:943.97K

Market Cap:97.25M

PE:-1.67

High:38.38

Open:37.00

Low:35.50

Close:38.20

52wk High:46.95

52wk Low:14.03

Shares:2.67M

Float Shares:611.50K

Volume Ratio:1.38

T/O Rate:4.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-21.8600

EPS(LYR):-66.8179

ROE:--

ROA:--

PB:-1.37

PE(LYR):-0.55

Loading ...

Overview Company News Filings

Yarrow Bioscience Files Amended 8-K Report on Merger Exchange Ratio Update

Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate

Benzinga Earnings

Yarrow Bioscience Q2 FY26 Net Loss Narrows to $6.51 Million; R&D Expenses Rise to $4.94 Million

Yarrow Bioscience Inc: Net Loss Totaled $6.5 Million for the Second Quarter of 2026

THOMSON REUTERS

Press Release: Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58

MT Newswires Live

Yarrow Bioscience Inc : Btig Initiates Coverage with Buy Rating; Target Price $58

THOMSON REUTERS

Vyne Therapeutics Issues Pre-funded Warrants for 133,290 Shares in Stock Exchange Deal

Yarrow Bioscience Finalizes Merger with VYNE, Starts Phase 2 Trial for Graves' Disease Drug YB-101

Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

MT Newswires Live

Press Release: Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of Yb-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease

VYNE Therapeutics trading halted, news pending

Top Premarket Decliners

MT Newswires Live

Vyne Therapeutics Set for 1-for-50 Reverse Stock Split on July 24

Vyne Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

THOMSON REUTERS

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

VYNE Therapeutics Announces Reverse Split and Merger Plans

Vyne Therapeutics Executes 1-for-50 Reverse Stock Split

Vyne Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/YARW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"YARW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YARW\",,,,,undefined,":{"symbol":"YARW","market":"US","secType":"STK","nameCN":"YARROW BIOSCIENCE, INC.","latestPrice":36.425,"timestamp":1787342400000,"preClose":38.2,"halted":0,"volume":25981,"hourTrading":{"tag":"盘后","latestPrice":36.425,"preClose":36.425,"latestTime":"19:30 EDT","volume":10,"amount":369.5,"timestamp":1787355005444,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04646596858638758,"floatShares":611500,"shares":2669800,"eps":-21.86,"marketStatus":"Market Closed","change":-1.775,"latestTime":"08-21 16:00:00 EDT","open":37,"high":38.38,"low":35.5,"amount":943966.2960069999,"amplitude":0.075393,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-21.86,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1516856400000,"exchange":"NASDAQ","adjPreClose":38.2,"postHourTrading":{"tag":"盘后","latestPrice":36.425,"preClose":36.425,"latestTime":"19:30 EDT","volume":10,"amount":369.5,"timestamp":1787355005444,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3824092677883641},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YARW\",,,,,undefined,":{"symbol":"YARW","floatShares":611500,"roa":"--","roe":"--","lyrEps":-66.817882,"volumeRatio":1.3824092677883641,"shares":2669800,"dividePrice":0,"high":38.38,"amplitude":0.075393,"preClose":38.2,"low":35.5,"week52Low":14.025,"pbRate":"-1.37","week52High":46.95,"institutionHeld":0,"latestPrice":36.425,"eps":-21.86,"divideRate":0,"volume":25981,"delay":0,"ttmEps":-21.86,"open":37,"prevYearClose":29.005,"prevWeekClose":42.49,"prevMonthClose":35.02,"prevQuarterClose":32.535,"fiveDayClose":42.49,"twentyDayClose":25.45,"sixtyDayClose":33.995},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/YARW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"YARW","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-2.14},{"market":"US","date":"2026-07-27","symbol":"YARW","defaultRemindTime":1785159000000,"type":"split","dateTimestamp":1785124800000,"forFactor":50,"toFactor":1,"ratio":50},{"date":"2026-07-24","symbol":"YARW","amount":0.40242,"announcedDate":"2026-07-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-22","defaultRemindTime":1784899800000,"name":"VYNE Therapeutics Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-23","payableDate":"2026-07-22","currency":"USD","dateTimestamp":1784865600000,"payDate":"2026-07-23"},{"market":"US","date":"2026-05-15","symbol":"YARW","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.08},{"date":"2026-02-27","symbol":"YARW","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772182800000,"name":null,"time":"Pre-MKt","dateTimestamp":1772168400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"YARW\",market:\"US\",,,undefined,":[{"executeDate":"2026-07-24","recordDate":"2026-07-22","paymentDate":"2026-07-23","value":0.40242,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"YARW\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1786680000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/YARW\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"YARW","date":"2026-08-21","current":-1.666285,"percent":1,"low":-0.423388,"twenty":-0.421318,"median":-0.411606,"eighty":-0.406626,"high":-0.376652,"avg":-0.410215,"sd":0.013222,"marketCap":106960000},"quantilePoints":[{"date":"2026-08-14","current":-0.421219,"twenty":-0.422047,"median":-0.421219,"eighty":-0.412759,"marketCap":119616000},{"date":"2026-08-21","current":-0.376652,"twenty":-0.421318,"median":-0.411606,"eighty":-0.406626,"marketCap":106960000}],"updateTime":1787453670211},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"YARW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659916788","title":"Yarrow Bioscience Files Amended 8-K Report on Merger Exchange Ratio Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659916788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659916788?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652189,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience files amended 8-K report on merger exchange ratio updateYarrow Bioscience filed an amended Form 8-K to update its audited financial statements to reflect the effects of the merger ex","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL730Jq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659315608","title":"Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315608","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315608?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:17","pubTimestamp":1786619844,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience (NASDAQ:YARW) reported quarterly losses of $(2.14) per share which missed the analyst consensus estimate of $(0.22) by 872.73 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61169365/yarrow-bioscience-q2-eps-2-14-misses-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","NDX","QQQA","IYW","QQQ","BK4007","QQQE","QLD","TQQQ","QID","MNQmain","TQQY","JEPQ","NQmain","SQQQ","GPIQ","NVIW.SI","QYLG","QQQM","QQQJ","TECS","ONEQ","QDTE","FTEC","QQQY",".IXIC","YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659155003","title":"Yarrow Bioscience Q2 FY26 Net Loss Narrows to $6.51 Million; R&D Expenses Rise to $4.94 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155003","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659155003?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618851,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience Q2 FY26 net loss narrows to $6.51 million; R&D expenses rise to $4.94 millionYarrow posted a net loss of $6.5 million in Q2 2026, with R&D expense of $4.9 million and G&A expense of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLbNhQ98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YARW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659569251","title":"Yarrow Bioscience Inc: Net Loss Totaled $6.5 Million for the Second Quarter of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659569251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659569251?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA12KT2J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YARW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659733155","title":"Press Release: Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659733155","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659733155?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618800,"startTime":"0","endTime":"0","summary":"--  The Company initiated the Phase 2a/2b trial of YB-101 in patients with. Graves' disease , with or without concurrent thyroid eye disease. --  The Phase 2a portion of the trial is a randomized,four cohorts designed to evaluate safety, pharmacokinetics ,pharmacodynamics , and efficacy over 24 weeks, including the. percentage of patients who are euthyroid and off anti-thyroid. drugs, as well as relevant measures of orbitopathy in patients. --  Topline results from the Phase 2a portion of the trial are. --  The Phase 2b portion of the trial is expected to commence in the. --  Licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4516","LU1169589451.USD","BK4187","WDGF","BK4566","BK4023","PD","PK","FOWF","SHLD","PPA","YB","BK4181","BK4218","BK4550","LU1169590202.USD","BK4173","GD","LU0170899867.USD","TSHR","YARW","BK4585","BK4588","KBWY","IDEF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656753413","title":"BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2656753413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656753413?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:20","pubTimestamp":1785756019,"startTime":"0","endTime":"0","summary":"BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["YARW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656237889","title":"Yarrow Bioscience Inc : Btig Initiates Coverage with Buy Rating; Target Price $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2656237889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656237889?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:27","pubTimestamp":1785752837,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN4400UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YARW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655038533","title":"Vyne Therapeutics Issues Pre-funded Warrants for 133,290 Shares in Stock Exchange Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2655038533","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655038533?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:13","pubTimestamp":1785442414,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics issues pre-funded warrants for 133,290 shares in stock exchange dealVyne Therapeutics entered an exchange agreement to issue pre-funded warrants for 133,290 common shares in exchange","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDLdzd4l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172460343","title":"Yarrow Bioscience Finalizes Merger with VYNE, Starts Phase 2 Trial for Graves' Disease Drug YB-101","url":"https://stock-news.laohu8.com/highlight/detail?id=1172460343","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172460343?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:01","pubTimestamp":1785160880,"startTime":"0","endTime":"0","summary":"Clinical-stage biotechnology company Yarrow Bioscience announced today that it has completed its merger with VYNE Therapeutics, simultaneously closing a roughly $200 million private placement...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","YB","VYNE","BK4173","YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654043338","title":"Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2654043338","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654043338?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:17","pubTimestamp":1785158242,"startTime":"0","endTime":"0","summary":"Yarrow Bioscience  said Monday that it has completed its merger with VYNE Therapeutics and the previously announced private financings totaling approximately $200 million.The combined company will operate as Yarrow Bioscience and its shares are expected to begin trading on the Nasdaq Capital Market on Tuesday under the ticker symbol YARW.The combined company will be led by President and Chief Executive Officer Rebecca Frey, Chief Operating Officer Rachael Alford, and Chief Financial Officer Tyler Zeronda.Bill Lundberg, former chief executive of biotech firm Merus, will become chairman of the board of directors.Yarrow said its lead product candidate, YB-101, is a potential first-in-class anti-thyroid-stimulating hormone receptor monoclonal antibody designed to directly disrupt the central mechanism driving both Graves' disease and thyroid eye disease in a single targeted treatment.The company also said it has initiated dosing in a Phase 2a/2b trial of YB-101 in patients with Graves' dis","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4173","YARW","YB","BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654145380","title":"Press Release: Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of Yb-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2654145380","media":"Dow Jones","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654145380?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":"Yarrow is advancing YB-101--a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves' disease (\"GD\") and thyroid eye disease (\"TED\")Dosing ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","VYNE","YB","YARW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654586460","title":"VYNE Therapeutics trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2654586460","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654586460?lang=en_us&edition=fundamental","pubTime":"2026-07-25 07:50","pubTimestamp":1784937027,"startTime":"0","endTime":"0","summary":"19:50 EDT VYNE Therapeutics (VYNE) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaki...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VYNE","YARW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653081426","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2653081426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653081426?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:43","pubTimestamp":1784893424,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics  shares were down 41% in Friday premarket trading  as the company's 1-for-50 reverse stock split is expected to become effective, with the shares to begin trading on a post-split basis on Monday.China SXT Pharmaceuticals  stock was down 27% after the company entered into a definitive securities purchase agreement for a registered direct offering of 4.5 million units at $2.00 per unit.Codexis  shares were down 26% after the company priced an underwritten public offering of about 16.7 million common shares at $1.50 per share.TDH  stock was down 19%, reversing the previous session's 13% decline.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CDXS","BK4121","YARW","BK4212","PETZ","BK4233","SXTC","BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653776155","title":"Vyne Therapeutics Set for 1-for-50 Reverse Stock Split on July 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2653776155","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653776155?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:50","pubTimestamp":1784839817,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics set for 1-for-50 reverse stock split on July 24Vyne Therapeutics plans a 1-for-50 reverse stock split effective July 24.Shares are set to trade on a split-adjusted basis on Nasdaq fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL7yTs4n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4112","LU2095319765.USD","BK4007","SG9999014039.USD","SG9999014021.USD","BK4588","VYNE","SG9999014013.SGD","SG9999014005.SGD","YARW","IE00B3QW5Z07.USD","LU2210150020.SGD","BCDF","LU2210149790.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653775048","title":"Vyne Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2653775048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653775048?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:26","pubTimestamp":1784838398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nTUA2FBLPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","YARW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653725779","title":"VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2653725779","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653725779?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:26","pubTimestamp":1784838360,"startTime":"0","endTime":"0","summary":"NEW YORK, July  23, 2026  (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its previously announced special cash dividend (the “Cash Dividend”),","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/23/3332602/0/en/VYNE-Therapeutics-Provides-Update-Regarding-Cash-Dividend-Reverse-Stock-Split-and-Anticipated-Timing-of-Closing-of-the-Proposed-Merger-with-Yarrow-Bioscience.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YARW","LCLG","TSHR","VYNE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270258","title":"VYNE Therapeutics Announces Reverse Split and Merger Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653270258?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:49","pubTimestamp":1784638171,"startTime":"0","endTime":"0","summary":"The latest update is out from VYNE Therapeutics ( ($VYNE) ). On July 21, 2026, VYNE Therapeutics’ board approved a 1-for-50 reverse stock split of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-announces-reverse-split-and-merger-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-announces-reverse-split-and-merger-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","YARW","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653827275","title":"Vyne Therapeutics Executes 1-for-50 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2653827275","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653827275?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:05","pubTimestamp":1784635540,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics executes 1-for-50 reverse stock splitVyne Therapeutics set a 1-for-50 reverse stock split tied to its proposed merger with Yarrow Bioscience.Post-split trading expected to start July","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDLbjWh2Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BCDF","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","BK4007","SG9999014005.SGD","NDAQ","SG9999014021.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","YARW","VYNE","LU2210149790.SGD","SG9999014013.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272971","title":"Vyne Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653272971?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUA8BNBK1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","YARW","VYNE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}